In Vitro Study of Leishmanicidal Activity of Biogenic Selenium Nanoparticles against Iranian Isolate of Sensitive and Glucantime-Resistant Leishmania tropica
Abstract
Background: Sensitive and glucantime (MA) resistance Leishmania tropica are referred to those isolates, which are responsive, or non-responsive to one or two full courses of treatment by MA systematically and/or intra-lesionally, respectively. In this study, we evaluated the antileishmanial activity of biogenic selenium nanoparticles (Se NPs) alone and in combination with MA against sensitive and glucantimeresistant L. tropica on in vitro model.
Methods: The Se NPs were synthesized by employing the Bacillus sp. MSh-1. The antileishmanial effects of Se NPs alone and in combination with MA on promastigote and amastigote stages of sensitive and glucantime-resistant L. tropica strains have been investigated using a colorimetric MTT assay and in a macrophage model. In addition hemolytic activity in type O+ human red blood cells and infectivity rate of the promastigotes before and after treatment with the Se NPs was evaluated.
Results: In the promastigote stage, various concentrations of Se NPs significantly inhibited (P<0.05) the growth of promastigotes of both strains in a dose-dependent manner. Similarly, Se NPs especially in combination with MA significantly reduced the mean number of amastigotes of both strains in each macrophage. Se NPs showed no hemolytic effect on human RBCs at low concentrations. Moreover, infection rate of macrophages by promastigotes significantly (P<0.05) was reduced when promastigotes pre-treated with Se NPs.
Conclusion: The findings of this study suggest a first step in the search of Se NPs as a new antileishmanial agent. Further experiments are needed to investigate antileishmanial effects of biogenic Se NPs on L. tropica using a clinical setting.
World Health Organization. Control of the Leishmaniasis. Geneva: WHO (TechnicalReport Series 949) 2010; 5-12.
Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol MicrobiolInfect Dis. 2004; 27: 305-18.
Sharifi F, Sharifi I, Zarean M Parizi MH,Aflatoonian M, Harandi MF, et al. Spatialdistribution and molecular identification ofLeishmania species from endemic foci of SoutheasternIran. Iran J Parasitol. 2012; 7(1): 45-52.
Noazin S, Khamesipour A, Moulton LH,Tanner M, Nasseri K, Modabber F, et al.Efficacy of killed whole-parasite vaccines in theprevention of leishmaniasis: a meta-analysis.Vaccine. 2009; 27(35): 4747-53.
Shirzadi MR, Gouya MM. National guidelinefor cutaneous leishmaniasis surveillance in Iran.Ministry of Health and Medical Education.Zoonoses control department, Tehran, I.R.Iran; 2010: pp 1-78.
Kazemi-Rad E, Mohebali M, Khadem-Erfan MB, Saffari M, Raoofian R, Hajjaran H, et al.Identification of antimony resistance markersin Leishmania tropica field isolates through acDNA-AFLP approach. Exp Parasitol. 2013;135(2): 344-9.
Pour R, Sharifi I, Kazemi B, Zarean M.Identification of nonresponsive isolates toGlucantime in patients with cutaneousleishmaniasis in Bam. J Kerman Univ Med Sci.2011; 18(2): 123-33.
Santos DO, Coutinho CE, Madeira MF,Bottino CG, Vieira RT, Nascimento SB, et al.Leishmaniasis treatment – a challenge thatremains: a review. Parasitol Res. 2004; 103: 1-10.
Mahmoudvand H, Sharififar F, Sharifi I,Ezatpour B, Fasihi Harandi M, Makki MS, etal. In vitro inhibitory effect of Berberis vulgaris(Berberidaceae) and its main component,Berberine against different Leishmania species.Iran J Parasitol. 2014; 9 (1): 28-36.
Shamsi Meymandi S, Javadi A, Dabiri S, ShamsiMeymandi M, Nadji M, et al. Comparativehistological and immuno-histochemical changesof dry type cutaneous leishmaniasis afteradministration of meglumine antimoniate,imiquimod or combination therapy. Arch IranMed. 2011; 14 (4): 238-43.
Firooz A, Khamesipour A, Ghoorchi MH,Nassiri-Kashani M, Eskandari SE, Khatami A,et al. Imiquimod in combination withmeglumine antimoniate for cutaneous leishmaniasis.Arch Dermatol. 2006; 142(12): 1575-9.
Shakibaie M, Khorramizadeh MR, FaramarziMR, Sabzevari O, Shahverdi AR. Biosynthesisand recovery of selenium nanoparticles and theeffects on matrix metalloproteinase-2 expression.Biotechnol Appl Biochem. 2010; 56: 7-15.
Rayman M. The importance of selenium to human health. Lancet. 2000; 356: 233-41.
Rayman M. Selenium in cancer prevention: areview of the evidence and mechanism of action.Proc Nutr Soc. 2005; 64(4): 527-42.
Whanger PD. Selenium and its relationship to cancer: an update. Br J Nutr. 2004; 91: 11-28.
Tran AP, Webster T. Selenium nanoparticlesinhibit Staphylococcus aureus growth. Inter JNano. 2011; 6: 1553-8.
Yang J, Huang K, Qin S, Wu X, Zhao Z, ChenF. Antibacterial action of selenium-enrichedprobiotics against pathogenic Escherichia coli.Dig Dis Sci. 2009; 54(2): 246-54.
Mahmoudvand H, Fasihi Harandi M, ShakibaieM, Aflatoonian MR, Makki MS, JahanbakhshS. Scolicidal effects of biogenic seleniumnanoparticles against protoscolices of hydatidcysts. Int J Surg. 2014 Mar 28. doi:10.1016/j.ijsu.2014.03.017. [Epub ahead ofprint].
Beheshti N, Soflaei S, Shakibaie M, Yazdi M,Ghaffarifar F, Dalimi AH, et al. Efficacy ofbiogenic selenium nanoparticles againstLeishmania major: In vitro and in vivo studies. JTrace Elem Med Biol. 2012; 27(3): 203-7.
Mahmoudvand H, Sepahvand P, JahanbakhshS, Azadpour M. Evaluation of antileishmanialand cytotoxicity effects of various extracts ofgarlic (Allium sativum) on Leishmania tropica. JParasit Dis. 2014 DOI: 10.1007/s12639-014-0520-9.
Mahmoudvand H, Sharifi I, Fasihi Harandi M,Shokohi M, Shakibaie M, Rezaei Riabi T, et al.Anti-leishmania effects of methotrexate (MTX)alone and in combination with meglumine antimoniate(MA) against Iranian isolate of sensitiveand MA-resistant Leishmania tropica: An invitroassay. Asian Pacific J Trop Med. 2014; 4:412-20.
Mahmoudvand H, Tavakoli R, Sharififar F,Minaie K, Ezatpour B, Jahanbakhsh B, et al.Leishmanicidal and cytotoxic activities of Nigellasativa and its active principle, thymoquinone.Pharm Biol. 2014 DOI:10.3109/13880209.2014.957784.
Valadares DG, Duarte MC, Oliveira JS, Chávez-Fumagalli MA, Martins VT, Costa LE. Leishmanicidalactivity of the Agaricus blazei Murill indifferent Leishmania species. Parasitol Int. 2011;60: 357-63.
Croft SL, Sundar S, Fairlamb AH. Drugresistance in leishmaniasis. Clin Microbiol Rev.2006; 19(1): 11-26.
Hadighi R, Boucher P, Khamesipour A,Meamar AR, Roy G, Ouellette M, et al.Glucantime-resistant Leishmania tropica isolatedfrom Iranian patients with cutaneous leishmaniasisare sensitive to alternative antileishmaniadrugs. Parasitol Res. 2007; 101(5): 1319-22.
Mohebali M, Fotouhi A, Hooshmand B, ZareiZ, Akhoundi B, Rahnema A, et al. Comparisonof miltefosine and meglumine antimoniate forthe treatment of zoonotic cutaneous leishmaniasis(ZCL) by a randomized clinical trial inIran. Acta Trop. 2007; 103: 33-40.
Mohebali M, Rezayat MM, Gilani K, Sarkar S,Akhoundi B, Esmaeili J. et al. Nanosilver in thetreatment of localized cutaneous leishmaniasiscaused by Leishmania major (MRHO/IR-/75/ER): an in vitro and in vivo study. Daru.2009; 17 (4): 285-9.
Torabi N , Mohebali M, Shahverdi AR,Rezayat SM, Edrissian GH, Esmaeili J, et al.Nanogold for the treatment of zoonoticcutaneous leishmaniasis caused by Leishmaniamajor (MRHO/IR/75/ER): An animal trialwith methanol extract of Eucalyptus camaldulensis.J Pharm Health Sci. 2011; 1(1): 15-18.
Baum MK, Shor-Posner G, Lai S, Zhang G,Lai H, Fletcher MA. High risk of HIV-relatedmortality is associated with selenium deficiency.J Acquir Immune Defic Syndr. 1997; 15: 370-4.
Yu M, Horng I, Chiang Y, Liaw Y, Chen C.Plasma selenium levels and the risk of hepatocellularcarcinoma among men with chronichepatitis virus infection. Am J Epidemiol. 1999;150: 367-74.
Yu S, Zhu Y, Li W. Protective role of seleniumagainst hepatitis B virus and primary liver cancerin Qidong. Biol Trace Elem Res. 1997; 56:117-24.
Lobanov AV, Gromer S, Salinas G, GladyshevVN. Selenium metabolism in Trypanosoma:characterization of selenoproteomes and identificationof a Kinetoplastid-specific selenoprotein.Nucleic Acids Res. 2006; 34: 4012-24.
Lira R, Sundar S, Makharia A, Kenney R, GamA, Saraiva E, Sakhs D. Evidence that the highincidence of treatment failure in Indian Kalaazar is due the emergence of antimony resistantstrains of Leishmania donovani. J Infect Dis. 1999;180(2): 564-7.
Shakibaie M, Shahverdi AR, Faramarzi MR,Hassanzadeh GR, Rahimi HR, Sabzevari O.Acute and subacute toxicity of novel biogenicselenium nanoparticles in mice. Pharma Biol.2013; 51(1): 58-63.
| Files | ||
| Issue | Vol 9 No 4 (2014) | |
| Section | Articles | |
| Keywords | ||
| Amastigote Cutaneous leishmaniasis Glucantime resistant Promastigote Selenium nanoparticles | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
